Gelmetix develops multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery for conditions like chronic lower back pain and osteoarthritis. Their lead product is a hydrogel for nucleus pulposus augmentation to relieve pain in patients suffering from Chronic Low Back Pain.
Gelmetix addresses the most common cause of this critical problem through an efficient, cost-effective, and drug-free approach to preventing pain and restoring functionality and movement. Our patented polymer gel helps to restore the natural integrity of the disc itself. Injected directly, it rehydrates and stabilizes, bringing back load-bearing properties and restoring the movement of the patient. Our polymer gel technology also has the potential to be adapted and extended for other uses. Gelmetix is a diversified therapeutic biomaterials company incorporated in the UK. It has offices in London, Paris, and Manchester.
Total Funding: £18.8 M
Funding Stage: Series C
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2012
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Gelmetix
